Company: HURA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-313799
Chunk: 13

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-10
Form: 424B5
Chunk 13
---

assurance that the market price of the Common Stock will ever equal or exceed the exercise price of the Warrants and consequently, whether it will ever be profitable for holders of the Warrants to exercise such Warrants.

S-9

USE OF PROCEEDS

We estimate that the net proceeds from the sale of securities in this offering will be approximately $14.4 million, after deducting
placement agent fees and commissions, as well as our estimated expenses related to the offering and assuming no exercise of any Warrants issued in this offering. If all of the Warrants offered in this offering are fully exercised for cash, we would
receive additional net proceeds of approximately $36.9 million. Further, we cannot predict when or if the Warrants will be exercised for cash. It is possible that the Warrants may expire and never be exercised.

We currently intend to use the net proceeds from the sale of the securities offered under this prospectus supplement for working capital,
satisfaction of the Company’s $3.4 million bridge note obligation to the Matthew Nachtrab Revocable Trust (net of $1.75 million invested by such lender into this offering), and general corporate purposes. The bridge note obligation
bears interest at a rate of 3% per month and requires repayment on the earlier of December 31, 2025 or on the date that is 30 days following the successful closing of an equity financing in which the Company receives gross cash proceeds in
excess of $12,000,000.

Although we have identified some potential uses of the net proceeds to be received from this offering, we cannot
specify these uses with certainty. Our management will have broad discretion in the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of this offering. Our stockholders may
not agree with the manner in which our management chooses to allocate and spend the net proceeds. Moreover, our management may use the net proceeds for corporate purposes that may not positively impact our results of operations or increase the
market value of our Common Stock.

Pending any use, as described above, we plan to deposit the net proceeds in money market accounts with
our primary bank or otherwise invest the net proceeds in high-quality, short-term, interest-bearing securities.

S-10

DESCRIPTION OF THE SECURITIES WE ARE OFFERING

We are offering shares of Common Stock, Warrants and Placement Agent Warrants (and the shares of our Common Stock issuable from time to time
upon